ClinicalTrials.gg
RecruitingNCT07864389miniCANUpdated Oct 13, 2026

Multimodal Approach Feasability Study for Untreated and Unruptured Intracranial Aneurysms

An interventional study of 3D CEUS in Aneurysm Cerebral (Unruptured), sponsored by Resolve Stroke. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-13.

Sponsored by Resolve Stroke · Not applicable, Interventional, and Diagnostic

How we know

Updated Oct 13, 2026Now RecruitingFirst site in France+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
15
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 66 studies in Intracranial Aneurysm with a site in France — 19 open to participants now, 26 under way, 1 of them phase 3. Intracranial Aneurysm · France.

Planned enrollment
22nd of 23
15 · median 171
Started
2026
with 5 others
No phase
18 of 66
8 open now
Primary completion
2026-11
later than 5 of 25 live
Registered
66th of 66
by date

Among the 66 studies in Intracranial Aneurysm with a site in France, this one is the 22nd largest by planned enrollment of the 23 interventional ones that give a count, is one of 6 that started in 2026, is one of 18 with no phase, reaches primary completion later than 5 of the 25 other live ones, and was the 66th registered.

Intracranial Aneurysm

419 studies on the registry are indexed under Intracranial Aneurysm; 118 are open to participants now.

Browse Intracranial Aneurysm studies →

Open to participants now

19 of the 66 studies in Intracranial Aneurysm with a site in France are open now. Recruiting first, the newest first:

13 more — sign in →

All 19 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 84 Intracranial Aneurysm studies recruiting now, 50 (60%) set no upper age limit and 15 (18%) stop at 75 or younger; 16 take children under 18; 6 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 66 studies in Intracranial Aneurysm with a site in France, or all of them as a file.
02

Study summary

This feasibility study aims to evaluate the SYLVER system's ability to visualize intracranial aneurysms in accordance with 3D rotational angiography (3DRA) as the reference technique.

03

Conditions studied

  • Aneurysm Cerebral (Unruptured)

Keywords

  • 3DRA
  • Ultrasound
  • CEUS
  • aneurysm
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult patients (≥ 18 years of age)
  • signed by the patient
  • Enrolled in a social security program or covered by an equivalent program
  • Presence of one or more unruptured, untreated intracranial aneurysms; typically bifurcation aneurysms, incidentally discovered, with a size of ≥ 3 mm; located at the base of the polygon of Willis in the Sylvian bifurcation, the anterior or posterior communicating artery, or the carotid or basilar terminal segments
  • Indications for diagnostic cerebral arteriography within a 6-month period following the discovery of one or more unruptured aneurysms

Exclusion criteria

Exclusion Criteria:

  • Unusable temporal window
  • Withdrawal of Consent by the Patient
  • Cancellation of the appointment for a cerebral angiography
  • At the investigator's initiative, in the patient's best interest
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
15 participants (estimated)

Study arms

  • Experimental
    SYLVER 3D CEUS and 3D Rotational Angiography

    Participants undergo their standard-of-care diagnostic cerebral angiography, including 3D rotational angiography (3DRA), during a day hospitalization. During the same visit, a single research acquisition of 3D contrast-enhanced transcranial ultrasound is performed with the SYLVER imaging system (investigational, non-invasive, class IIa, not CE-marked) through the temporal acoustic window, after intravenous injection of an ultrasound contrast agent (SonoVue®). The research procedure lasts up to 30 minutes. Qualitative and quantitative hemodynamic parameters of the aneurysmal sac obtained with SYLVER are compared with 3DRA as the reference technique. Follow-up is limited to the day of the procedure.

    Device: 3D CEUS

Interventions

  • Device3D CEUS

    SYLVER is the investigational, non-invasive, class IIa ultrasound imaging system providing three-dimensional contrast-enhanced ultrasound (3D CEUS) imaging of the cerebral vasculature through the skull. Transcranial 3D CEUS acquisition is performed via the temporal acoustic window during the day-hospitalization for standard-of-care follow-up cerebral angiography, for a maximum of 30 minutes. Acquisitions are used to assess aneurysm presence, location and shape, intrasaccular flow organization (jet, recirculation, stagnation), filling completeness, and time-intensity curve and flow velocity parameters (time of arrival, time to peak, pulsatility index), which are compared with 3D rotational angiography.

06

What researchers measure

Primary outcomes

  1. Qualitative agreement between SYLVER 3D CEUS and 3D Rotational Angiography for aneurysmal sac hemodynamic analysis

    Agreement between SYLVER 3D contrast-enhanced ultrasound and 3D rotational angiography (3DRA, reference technique) for qualitative parameters: aneurysm presence, location and shape; intrasaccular flow organization (jet, recirculation, stagnation); complete or partial sac filling. Agreement is expressed as observed percent agreement and, where relevant, kappa coefficient. Analysis is descriptive; no success threshold or statistical hypothesis is pre-specified.

    Time frame: Day 1

  2. Quantitative agreement between SYLVER 3D CEUS and 3D Rotational Angiography for aneurysmal sac hemodynamic parameters

    Association and agreement between SYLVER 3D CEUS and 3DRA for quantitative hemodynamic parameters of the aneurysmal sac derived from the time-intensity curve (time of arrival, time to peak) and flow velocity (notably pulsatility index), analyzed in relation to intrasaccular flow organization. Association is assessed by Spearman correlation coefficient with 95% CI, and agreement by Bland-Altman limits of agreement. Analysis is descriptive.

    Time frame: Day 1

Secondary outcomes

  1. Feasibility of the multimodal angiography and 3D Ultrasound approach

    Number and percentage (with 95% CI) of participants with usable angiographic and ultrasound acquisitions, feasible co-registration of both modalities, and interpretable hemodynamic analysis of the aneurysmal sac.

    Time frame: Day 1

  2. Healthcare staff time with SYLVER

    Time (minutes) spent by physicians, nursing assistants, radiographers and radiologists, measured with SYLVER.

    Time frame: Day 1

  3. Associated costs with SYLVER

    Costs (euros) associated with the measured staff time, with SYLVER, to estimate the medico-economic impact of SYLVER use.

    Time frame: Day 1

  4. Incidence of Adverse Events, Serious Adverse Events and Device Deficiencies

    Number and percentage of participants with adverse events (AEs) and serious adverse events (SAEs), and number of SYLVER device deficiencies, recorded in the eCRF.

    Time frame: From inclusion to end of participation (Day 1)

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Wendl CM, Eiglsperger J, Schuierer G, Jung EM. Evaluating post-interventional occlusion grades of cerebral aneurysms with transcranial contrast-enhanced ultrasound (CEUS) using a matrix probe. Ultraschall Med. 2015 Apr;36(2):168-73. doi: 10.1055/s-0034-1398835. Epub 2015 Jan 21. PubMed 25607631 ↗
  • Perren F, Horn P, Kern R, Bueltmann E, Hennerici M, Meairs S. A rapid noninvasive method to visualize ruptured aneurysms in the emergency room: three-dimensional power Doppler imaging. J Neurosurg. 2004 Apr;100(4):619-22. doi: 10.3171/jns.2004.100.4.0619. PubMed 15070114 ↗
  • White PM, Wardlaw JM, Teasdale E, Sloss S, Cannon J, Easton V. Power transcranial Doppler ultrasound in the detection of intracranial aneurysms. Stroke. 2001 Jun;32(6):1291-7. doi: 10.1161/01.str.32.6.1291. PubMed 11387489 ↗
  • Newell DW, Winn HR. Transcranial Doppler in cerebral vasospasm. Neurosurg Clin N Am. 1990 Apr;1(2):319-28. PubMed 2136144 ↗
  • Fung C, Heiland DH, Reitmeir R, Niesen WD, Raabe A, Eyding J, Schnell O, Rolz R, Z Graggen WJ, Beck J. Ultrasound Perfusion Imaging for the Detection of Cerebral Hypoperfusion After Aneurysmal Subarachnoid Hemorrhage. Neurocrit Care. 2022 Aug;37(1):149-159. doi: 10.1007/s12028-022-01460-z. Epub 2022 Feb 24. PubMed 35211837 ↗
  • Yoon DY, Lim KJ, Choi CS, Cho BM, Oh SM, Chang SK. Detection and characterization of intracranial aneurysms with 16-channel multidetector row CT angiography: a prospective comparison of volume-rendered images and digital subtraction angiography. AJNR Am J Neuroradiol. 2007 Jan;28(1):60-7. PubMed 17213425 ↗
  • Sliwczynski A, Jewczak M, Dorobek M, Furlepa K, Golebiak I, Skibinska E, Sarzynska-Dlugosz I. An Analysis of the Incidence and Cost of Intracranial Aneurysm and Subarachnoid Haemorrhage Treatment between 2013 and 2021. Int J Environ Res Public Health. 2023 Feb 21;20(5):3828. doi: 10.3390/ijerph20053828. PubMed 36900834 ↗

Individual participant data

Plan to share: No

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Oct 2026; primary completion for Nov 2026, 1 month later.

Of 47 industry-sponsored interventional studies with no phase under Intracranial Aneurysm, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 49. This study's planned 1 month is below that.

Counting every sponsor, half of 106 studies reached it within 39 months; a quarter within 22 and three quarters within 69.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 29, 2026
First posted
Oct 7, 2026
StartEst.
Oct 5, 2026
Primary completionEst.
Nov 2026
CompletionEst.
Dec 2026
Last update
Oct 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 13, 2026
Sites
1 site added — first site in France
Show site
  • Nantes University Hospital · Nantes, France
Oct 13, 2026
Sponsor
Collaborators added: Nantes University Hospital; collaborators removed: Centre Hospitalier Universitaire de Nantes, Nantes, France
Oct 13, 2026
Registered
First appeared on the registry
Oct 7, 2026
Show all 2 updates
  1. Oct 13, 2026
    Not yet recruiting→Recruiting
    1 site added — first site in France
    Show site
    • Nantes University Hospital · Nantes, France
    Sponsor Collaborators added: Nantes University Hospital; collaborators removed: Centre Hospitalier Universitaire de Nantes, Nantes, France
  2. Oct 7, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07864389
Lead sponsor
Resolve Stroke
Responsible party
Sponsor
First posted
Oct 7, 2026
Start date
Oct 5, 2026 (estimated)
Primary completion
Nov 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Oct 13, 2026

Study contacts

Jonathan Lavaud, PhD
Contact
jonathan.lavaud@resolvestroke.com
+33750529940

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion